The Challenge of Reducing Complexity of Heart Failure Treatment Without Losing Efficacy: Quo Vadis?

J Am Coll Cardiol. 2022 Aug 9;80(6):595-597. doi: 10.1016/j.jacc.2022.05.028.

Authors

Edimar Alcides Bocchi¹, Ivna Girard Cunha Vieira Lima²

Affiliations

¹ Heart Failure Clinics, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil. Electronic address: [email protected].
² Heart Failure Clinics, Instituto do Coracao, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

PMID: 35926932
DOI: 10.1016/j.jacc.2022.05.028

No abstract available

Keywords: chronic heart failure; heart rate; ivabradine; systolic dysfunction.

Publication types

Editorial
Comment

MeSH terms

Benzazepines / pharmacology
Cardiovascular Agents* / therapeutic use
Heart Failure* / drug therapy
Heart Failure, Systolic* / drug therapy
Heart Rate
Humans
Ivabradine
Treatment Outcome

Substances

Benzazepines
Cardiovascular Agents
Ivabradine